E30.1 Insurance Policy Changes

ICD-10 E30.1 is officially defined as "Precocious puberty." code E30.1 is referenced in 8 tracked payer policy changes from Blue Cross & Blue Shield of Mississippi and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code E30.1 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross & Blue Shield of Mississippi · Identified Sep 29, 2026High impact
Leuprolide
BCBSMS requires prior authorization for Lupron (leuprolide acetate), and Lupron may be considered medically necessary for endometriosis, uterine leiomyomata, central precocious puberty or prostate cancer when the documented criteria are met. The 08/01/2026 revision states that prior authorization is required for Lupron and adds Eligard and leuprolide acetate depot as medically necessary for advanced prostate cancer. Camcevi, Lutrate Depot, Vabrinty and Fensolvi are not covered on any BCBSMS Formulary.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026High impact
Lupron (leuprolide acetate)
Prior authorization is required for Lupron (leuprolide). The 08/01/2026 revision adds medically necessary coverage for Eligard (leuprolide acetate) and leuprolide acetate depot for advanced prostate cancer, and it lists Camcevi (leuprolide), Lutrate Depot (leuprolide acetate kit), Vabrinty (leuprolide acetate) and Fensolvi (leuprolide acetate) as not covered on any BCBSMS Formulary. Lupron may be considered medically necessary for endometriosis, uterine leiomyomata, central precocious puberty, or prostate cancer when the initial criteria for that indication are documented.
Aetna · Identified Oct 18, 2026Medium impact
Gonadotropin-Releasing Hormone Analogs and Antagonists (CPB 0501, reviewed 2026-10-14)
Aetna considers gonadotropin-releasing hormone (GnRH) analogs and antagonists medically necessary for commercial plan members only for the specific indications listed for each drug, including leuprolide, goserelin, histrelin, triptorelin, degarelix, cetrorelix and ganirelix, and treats all other indications as experimental, investigational or unproven. Each drug has separate criteria for initial approval and for continuation of therapy, and continuation for prostate cancer requires clinical benefit such as serum testosterone less than 50 ng/dL and no unacceptable toxicity. Precertification is required for the prostate cancer indication, and gender dysphoria treatment for members under 18 must be prescribed by or in consultation with a provider specialized in the care of transgender youth who has collaborated care with a mental health provider.
Blue Cross & Blue Shield of Mississippi · Identified Sep 29, 2026Medium impact
State and School Employees' Health Insurance Plan - Leuprolide
Eligard and leuprolide acetate depot are medically necessary for advanced prostate cancer under the State Health Plan. Camcevi, Lutrate Depot, Vabrinty and Fensolvi are not covered on the State Health Plan Medical Drug Formulary. Lupron may be considered medically necessary for endometriosis or uterine leiomyomata in individuals 18 or older who are not pregnant and will use non-hormonal contraception, for central precocious puberty when the listed criteria are documented, or for advanced prostate cancer.
Aetna · Identified Aug 17, 2026Medium impact
Genetic Counseling (CPB 0189, reviewed 2026-03-27)
Aetna considers genetic counseling medically necessary for listed pregnancy-related indications, including couples who are closely related genetically, familial cancer disorders, pregnant women with maternal age 35 years or greater at delivery, and parents of a child born with a genetic disorder or birth defect. Genetic counseling unrelated to pregnancy is covered when it is appropriate for, or provided with, medically necessary genetic testing in accordance with ACMG guidelines. Genetic counseling for all other indications is considered experimental, investigational or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Gonadotropin-Releasing Hormone Analogs and Antagonists (CPB 0501, reviewed 2026-07-10)
Aetna covers gonadotropin-releasing hormone (GnRH) analogs and antagonists under its commercial medical plans for the indications the policy lists, including prostate cancer, breast cancer, ovarian cancer, central precocious puberty, endometriosis, uterine leiomyomata (fibroids), and ovulation induction or assisted reproductive technology. The policy also sets criteria for gender dysphoria treatment, including pubertal suppression in adolescents and gender transition, and for continuation of therapy. Aetna considers all other indications experimental, investigational, or unproven.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Luteinizing Hormone (LH) Testing
Measurement of luteinizing hormone is medically necessary to distinguish between pituitary, hypothalamus and gonad disorders in males with hypogonadism or hypergonadism. It is also medically necessary for females with symptoms of ovarian dysfunction. Measurement of luteinizing hormone is not medically necessary when performed for screening in asymptomatic patients.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Estrogen Hormone Testing: Estradiol and Estrone
Measurement of estrogen hormones is considered medically necessary to evaluate ovarian function in females with symptoms of hypoestrogenism or hyperestrogenism, to diagnose hyperestrogenism in symptomatic males, to monitor hormone replacement therapy in postmenopausal females, and to monitor antiestrogen therapy. Measurement of estrogen hormones is considered not medically necessary when performed for screening purposes in asymptomatic patients. The covered tests are total estradiol (CPT 82670), fractionated estrogens (CPT 82671), total estrogens (CPT 82672), estrone (CPT 82679), and free estradiol by direct measurement, such as equilibrium dialysis (CPT 82681).

Watch E30.1

Get one email when a payer policy names E30.1, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code E30.1?

There are 8 tracked policy changes affecting code E30.1, including updates from Blue Cross & Blue Shield of Mississippi, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code E30.1?

Payers that have issued tracked updates for code E30.1 include: Blue Cross & Blue Shield of Mississippi, Aetna.

How do I get notified when code E30.1 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code E30.1. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code E30.1?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Leuprolide

Lupron (leuprolide acetate)

Gonadotropin-Releasing Hormone Analogs and Antagonists (CPB 0501, reviewed 2026-10-14)

State and School Employees' Health Insurance Plan - Leuprolide

Genetic Counseling (CPB 0189, reviewed 2026-03-27)

Gonadotropin-Releasing Hormone Analogs and Antagonists (CPB 0501, reviewed 2026-07-10)

Luteinizing Hormone (LH) Testing

Estrogen Hormone Testing: Estradiol and Estrone

What insurance policy changes affect code E30.1?

Which payers have updated policy for code E30.1?

How do I get notified when code E30.1 policy changes?

Why do payers change policies for code E30.1?